



HYPERA S.A.

Publicly held Company

Corporate Taxpayer ID (CNPJ/MF) No. 02.932.074/0001-91

Company Registry (NIRE) No. 35.300.353.251

CVM Code No. 21431

NOTICE TO THE MARKET

HYPERA S.A. (“**Company**” or “**Hypera Pharma**”), informs its shareholders, and the market in general, attending to the provisions of article 157, §4, of Law No. 6.404, of December 15th, 1976, as amended, and the Brazilian Securities Commission's (“**CVM**”) Resolution No. 44, of August 23rd, 2021, as amended, that at the meeting held on December 14th, 2023, by the Company's Board of Directors, was approved the Company's 17th (seventeenth) issuance of simple debentures, non-convertible into shares, unsecured, in a single series, for public offering under automatic distribution registration (“**Debentures**” and “**Issuance**”, respectively), attending to the provisions of the CVM Resolution No. 160, of July 13th, 2022, as amended, so that 600,000 (six hundred thousand) Debentures will be issued, with a unit face value of BRL 1,000.00 (one thousand Reais), in the total amount of BRL 600,000,000.00 (six hundred million Reais), with a term of maturity of 5 (five) years, from the issuance date, December 15th, 2023.

The Debentures are entitled to a remuneration equivalent to 100.00% (one hundred percent) of the daily variation of the DI Rate, "over extragroup" and surcharge of 1,30% (one integer and thirty hundredths percent) per base year, 252 (two hundred and fifty-two) business days. The funds obtained through the Issuance will be used for the Company's cash flow reinforcement.

São Paulo, December 14th, 2023.

HYPERA S.A.

Adalmario Ghovatto Satheler do Couto

Investor Relations Officer